Advertisement
Document › Details
Exscientia plc. (8/28/24). "Press Release: Exscientia to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference". Oxford.
Exscientia plc (Nasdaq: EXAI) today announced that David Hallett, interim Chief Executive Officer and Chief Scientific Officer, will participate in a fireside chat at the Morgan Stanley 22 nd Annual Global Healthcare Conference on Wednesday, September 4, 2024 at 7:00 a.m. EDT (12:00 p.m. BST).
A live webcast of the fireside chat will be available on the Company’s website, under the “Investors & Media” section at investors.exscientia.ai . An archived replay of the webcast will be available for approximately 30 days following the presentation.
About Exscientia
Exscientia is a technology-driven drug design and development company, committed to creating more effective medicines for patients, faster. Exscientia combines precision design with integrated experimentation, aiming to invent and develop the best possible drugs in the most efficient manner. Operating at the interfaces of human ingenuity, artificial intelligence (AI), automation and physical engineering, we pioneered the use of AI in drug discovery as the first company to progress AI-designed small molecules into a clinical setting. We have developed an internal pipeline focused on oncology, while our partnered pipeline extends to many other therapeutic areas. By leading this new approach to drug creation, we believe we can change the underlying economics of drug discovery and rapidly advance the best scientific ideas into medicines for patients.
For more information visit us on www.exscientia.com or follow us on LinkedIn @ex-scientia and X @exscientiaAI .
Investor Relations:
Sara Sherman / Chinedu Okeke
investors@exscientia.ai
Media:
David Keown
media@exscientia.ai
Record changed: 2024-09-11 |
Advertisement
More documents for Recursion Pharmaceuticals (Group)
- [1] Recursion Pharmaceuticals, Inc.. (8/8/24). "Press Release: Recursion and Exscientia Enter Definitive Agreement to Create a Global Technology-Enabled Drug Discovery Leader with End-to-End Capabilities". Salt Lake City, UT & Oxford....
- [2] Recursion Pharmaceuticals, Inc.. (4/16/24). "Press Release: Recursion Appoints Najat Khan, PhD, as Chief R&D Officer and Chief Commercial Officer". Salt Lake City, UT....
- [3] BioIndustry Assocation (BIA). (1/30/24). "Press Release: BIA Reaches 600 Member Companies, Announces New Board and Leadership Restructure". Paris....
- [4] Exscientia plc. (12/5/23). "Press Release: Exscientia Receives Open Philanthropy Grant to Explore New Therapeutic Approach for Pandemic Influenza". Oxford....
- [5] Exscientia plc. (11/21/23). "Press Release: Exscientia to Present at the 6th Annual Evercore ISI HealthCONx Conference". Oxford....
- [6] Exscientia plc. (10/17/23). "Press Release: Parker Moss to Join Exscientia as EVP, Corporate Development". Oxford....
- [7] Exscientia plc. (10/3/23). "Press Release: Exscientia Details Pipeline Prioritisation Strategy". Oxford....
- [8] Exscientia plc. (9/20/23). "Press Release: Exscientia Announces AI Drug Discovery Collaboration with Merck KGaA, Darmstadt, Germany". Oxford....
- [9] Merck KGaA. (9/20/23). "Press Release: Merck Enters Two Strategic Collaborations to Strengthen AI-driven Drug Discovery [Not intended for US-, Canada- or UK-based media]". Darmstadt....
- [10] Exscientia plc. (8/31/23). "Press Release: Exscientia to Present at Upcoming Investor Conferences in September". Oxford....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement
» top